These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34723709)

  • 21. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study.
    Golder V; Kandane-Rathnayake R; Huq M; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Sockalingam S; Navarra SV; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand EF;
    Lancet Rheumatol; 2019 Oct; 1(2):e103-e110. PubMed ID: 38229337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
    Hao Y; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Zhang Z
    Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35241499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lupus low disease activity state as a treatment target for pediatric patients with lupus nephritis.
    Kisaoglu H; Baba O; Kalyoncu M
    Pediatr Nephrol; 2023 Apr; 38(4):1167-1175. PubMed ID: 36156735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
    Petri M; Magder LS
    Arthritis Rheumatol; 2018 Nov; 70(11):1790-1795. PubMed ID: 29806142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study.
    Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Cho J; Lateef A; Hamijoyo L; Luo SF; Wu YJ; Navarra SV; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake BMDB; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Yu D; Karyekar CS; Sing Lau C; Monk JA; Nikpour M; Hoi A; Morand EF;
    Lancet Rheumatol; 2022 Dec; 4(12):e822-e830. PubMed ID: 38261390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
    Tsang-A-Sjoe MW; Bultink IE; Heslinga M; Voskuyl AE
    Rheumatology (Oxford); 2017 Jan; 56(1):121-128. PubMed ID: 27803306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS).
    Abdelhady EI; Rabie M; Hassan RA
    Clin Rheumatol; 2021 Nov; 40(11):4553-4558. PubMed ID: 34142298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Achieving Lupus Low Disease Activity State Fifty Percent of the Time With Both Reduced Damage Accrual and Mortality in Patients With Systemic Lupus Erythematosus.
    Sharma C; Raymond W; Eilertsen G; Nossent J
    Arthritis Care Res (Hoboken); 2020 Mar; 72(3):447-451. PubMed ID: 30821926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.
    Oon S; Huq M; Golder V; Ong PX; Morand EF; Nikpour M
    Ann Rheum Dis; 2019 May; 78(5):629-633. PubMed ID: 30679152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).
    Franklyn K; Lau CS; Navarra SV; Louthrenoo W; Lateef A; Hamijoyo L; Wahono CS; Chen SL; Jin O; Morton S; Hoi A; Huq M; Nikpour M; Morand EF;
    Ann Rheum Dis; 2016 Sep; 75(9):1615-21. PubMed ID: 26458737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epstein-Barr Virus Reactivation as a New Predictor of Achieving Remission or Lupus Low Disease Activity State in Patients with Systemic Lupus Erythematosus with Cutaneous Involvement.
    Miskovic R; Cirkovic A; Miljanovic D; Jeremic I; Grk M; Basaric M; Lazarevic I; Stojanovic M; Plavsic A; Raskovic S; Banko A
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity.
    Babaoğlu H; Li J; Goldman D; Magder LS; Petri M
    Arthritis Care Res (Hoboken); 2020 Feb; 72(2):225-232. PubMed ID: 31507071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting DORIS Remission and LLDAS in SLE: A Review.
    Parra Sánchez AR; van Vollenhoven RF; Morand EF; Bruce IN; Kandane-Rathnayake R; Weiss G; Tummala R; Al-Mossawi H; Sorrentino A
    Rheumatol Ther; 2023 Dec; 10(6):1459-1477. PubMed ID: 37798595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus.
    Samões B; Zen M; Abelha-Aleixo J; Gatto M; Doria A
    Autoimmun Rev; 2022 Oct; 21(10):103165. PubMed ID: 35931316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort.
    Tani C; Vagelli R; Stagnaro C; Carli L; Mosca M
    Lupus Sci Med; 2018; 5(1):e000234. PubMed ID: 29531772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Articular involvement, steroid treatment and fibromyalgia are the main determinants of patient-physician discordance in systemic lupus erythematosus.
    Elefante E; Tani C; Stagnaro C; Signorini V; Parma A; Carli L; Zucchi D; Ferro F; Mosca M
    Arthritis Res Ther; 2020 Oct; 22(1):241. PubMed ID: 33054823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus.
    Emamikia S; Oon S; Gomez A; Lindblom J; Borg A; Enman Y; Morand E; Grannas D; van Vollenhoven RF; Nikpour M; Parodis I
    Rheumatology (Oxford); 2022 Nov; 61(12):4752-4762. PubMed ID: 35302581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges of achieving clinical remission in a national cohort of juvenile-onset systemic lupus erythematosus patients.
    Abdelrahman N; Beresford MW; Leone V;
    Lupus; 2019 Apr; 28(5):667-674. PubMed ID: 30943853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does expert opinion match the definition of lupus low disease activity state? Prospective analysis of 500 patients from a Spanish multicentre cohort.
    Altabás-González I; Rúa-Figueroa I; Rubiño F; Mouriño Rodríguez C; Hernández-Rodríguez I; Menor Almagro R; Uriarte Isacelaya E; Tomero Muriel E; Salman-Monte TC; Carrión-Barberà I; Galindo M; Rodríguez Almaraz EM; Jiménez N; Inês L; Pego-Reigosa JM
    Rheumatology (Oxford); 2023 Mar; 62(3):1162-1169. PubMed ID: 35961050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups.
    Massias JS; Smith EMD; Al-Abadi E; Armon K; Bailey K; Ciurtin C; Davidson J; Gardner-Medwin J; Haslam K; Hawley DP; Leahy A; Leone V; McErlane F; Mewar D; Modgil G; Moots R; Pilkington C; Ramanan AV; Rangaraj S; Riley P; Sridhar A; Wilkinson N; Beresford MW; Hedrich CM
    Lupus; 2020 Apr; 29(5):474-481. PubMed ID: 32233733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.